Related Experiment Videos
L6 monoclonal antibody binds prostate cancer
R T O'Donnell1, S J DeNardo, X B Shi
1Department of Internal Medicine, University of California Davis Medical Center, Sacramento, USA. rtodonnell@ucdavis.edu
The Prostate
|October 6, 1998
Summary
The L6 monoclonal antibody effectively targets prostate cancer cells and xenografts in mice. This antibody shows promise for radioimmunotherapy (RIT) of prostate cancer due to its specific targeting and low normal organ uptake.
Area of Science:
- Oncology
- Immunology
- Radiopharmaceutical Therapy
Background:
- Radioimmunotherapy (RIT) offers targeted systemic delivery of radionuclides for androgen-independent metastatic prostate cancer.
- Effective RIT necessitates antibodies with high specificity for malignant cells and favorable pharmacokinetics.
Purpose of the Study:
- To evaluate the specificity and efficacy of the L6 monoclonal antibody for targeting prostate cancer.
- To assess the biodistribution and pharmacokinetics of radiolabeled L6 antibody in preclinical models.
Main Methods:
- Enzyme-linked immunoabsorbent assay (ELISA), radioimmunoassay, and immunofluorescent staining were used to determine L6 antibody binding.
- Biodistribution, tumor uptake, and clearance studies of 125I-L6 were conducted in nude mice with human prostate cancer xenografts.
Main Results:
- The L6 monoclonal antibody demonstrated strong binding to prostate cancer cell lines (PC3, DU145) and live PC3 cells (66%).
- In vivo studies showed specific targeting of prostate cancer xenografts in mice, with approximately 10% injected dose uptake.
- Low uptake in normal organs and consistent blood clearance were observed.
Conclusions:
- The L6 monoclonal antibody exhibits specific targeting of human prostate cancer xenografts in vivo.
- The antibody demonstrates favorable biodistribution with low normal organ uptake.
- Further investigation of radiolabeled L6 antibody for prostate cancer radioimmunotherapy is warranted.